The Role of Complement Dysregulation in Glaucoma

Overview

Journal Int J Mol Sci

Publisher MDPI

Specialties Biochemistry
Chemistry
Molecular Biology

Date 2024 Feb 24

PMID 38396986

Authors

Cindy Hoppe

Meredith Gregory-Ksander

Affiliations

Soon will be listed here.

Abstract

Glaucoma is a progressive neurodegenerative disease characterized by damage to the optic nerve that results in irreversible vision loss. While the exact pathology of glaucoma is not well understood, emerging evidence suggests that dysregulation of the complement system, a key component of innate immunity, plays a crucial role. In glaucoma, dysregulation of the complement cascade and impaired regulation of complement factors contribute to chronic inflammation and neurodegeneration. Complement components such as C1Q, C3, and the membrane attack complex have been implicated in glaucomatous neuroinflammation and retinal ganglion cell death. This review will provide a summary of human and experimental studies that document the dysregulation of the complement system observed in glaucoma patients and animal models of glaucoma driving chronic inflammation and neurodegeneration. Understanding how complement-mediated damage contributes to glaucoma will provide opportunities for new therapies.

Citing Articles

Exosomes in Regulating miRNAs for Biomarkers of Neurodegenerative Disorders.

Sivalingam A, Sureshkumar D Mol Neurobiol. 2025; .

PMID: 39918711 DOI: 10.1007/s12035-025-04733-8.

Increased Pan-Type, A1-Type, and A2-Type Astrocyte Activation and Upstream Inflammatory Markers Are Induced by the P2X7 Receptor.

Campagno K, Sripinun P, See L, Li J, Lu W, Jassim A Int J Mol Sci. 2024; 25(16).

PMID: 39201471 PMC: 11354399. DOI: 10.3390/ijms25168784.

Corneal application of SOCS1/3 peptides for the treatment of eye diseases mediated by inflammation and oxidative stress.

Ahmed C, Johnson H, Lewin A Front Immunol. 2024; 15:1416181.

PMID: 39104531 PMC: 11298391. DOI: 10.3389/fimmu.2024.1416181.

Advances in aqueous humor proteomics for biomarker discovery and disease mechanisms exploration: a spotlight on primary open angle glaucoma.

Beutgen V, Graumann J Front Mol Neurosci. 2024; 17:1397461.

PMID: 38721264 PMC: 11076703. DOI: 10.3389/fnmol.2024.1397461.

References

Howell G, Macalinao D, Sousa G, Walden M, Soto I, Kneeland S . Molecular clustering identifies complement and endothelin induction as early events in a mouse model of glaucoma. J Clin Invest. 2011; 121(4):1429-44. PMC: 3069778. DOI: 10.1172/JCI44646. View

Hubens W, Mohren R, Liesenborghs I, Eijssen L, Ramdas W, Webers C . The aqueous humor proteome of primary open angle glaucoma: An extensive review. Exp Eye Res. 2020; 197:108077. DOI: 10.1016/j.exer.2020.108077. View

Panagis L, Zhao X, Ge Y, Ren L, Mittag T, Danias J . Gene expression changes in areas of focal loss of retinal ganglion cells in the retina of DBA/2J mice. Invest Ophthalmol Vis Sci. 2009; 51(4):2024-34. PMC: 2868411. DOI: 10.1167/iovs.09-3560. View

Ahmed F, Brown K, Stephan D, Morrison J, Johnson E, Tomarev S . Microarray analysis of changes in mRNA levels in the rat retina after experimental elevation of intraocular pressure. Invest Ophthalmol Vis Sci. 2004; 45(4):1247-58. DOI: 10.1167/iovs.03-1123. View

Kliuchnikova A, Samokhina N, Ilina I, Karpov D, Pyatnitskiy M, Kuznetsova K . Human aqueous humor proteome in cataract, glaucoma, and pseudoexfoliation syndrome. Proteomics. 2016; 16(13):1938-46. DOI: 10.1002/pmic.201500423. View

Sun Y, Wirta D, Murahashi W, Mathur V, Sankaranarayanan S, Taylor L . Safety and Target Engagement of Complement C1q Inhibitor ANX007 in Neurodegenerative Eye Disease: Results from Phase I Studies in Glaucoma. Ophthalmol Sci. 2023; 3(2):100290. PMC: 10130689. DOI: 10.1016/j.xops.2023.100290. View

Gonzalez-Iglesias H, Alvarez L, Garcia M, Escribano J, Rodriguez-Calvo P, Fernandez-Vega L . Comparative proteomic study in serum of patients with primary open-angle glaucoma and pseudoexfoliation glaucoma. J Proteomics. 2013; 98:65-78. DOI: 10.1016/j.jprot.2013.12.006. View

Kuehn M, Kim C, Ostojic J, Bellin M, Alward W, Stone E . Retinal synthesis and deposition of complement components induced by ocular hypertension. Exp Eye Res. 2006; 83(3):620-8. DOI: 10.1016/j.exer.2006.03.002. View

Hourcade D . Properdin and complement activation: a fresh perspective. Curr Drug Targets. 2008; 9(2):158-64. DOI: 10.2174/138945008783502458. View

10.

Esporcatte B, Tavares I . Normal-tension glaucoma: an update. Arq Bras Oftalmol. 2016; 79(4):270-6. DOI: 10.5935/0004-2749.20160077. View

11.

Takabayashi T, Vannier E, Clark B, Margolis N, Dinarello C, Burke J . A new biologic role for C3a and C3a desArg: regulation of TNF-alpha and IL-1 beta synthesis. J Immunol. 1996; 156(9):3455-60. View

12.

Williams P, Tribble J, Pepper K, Cross S, Morgan B, Morgan J . Inhibition of the classical pathway of the complement cascade prevents early dendritic and synaptic degeneration in glaucoma. Mol Neurodegener. 2016; 11:26. PMC: 4822272. DOI: 10.1186/s13024-016-0091-6. View

13.

Hageman G, Anderson D, Johnson L, Hancox L, Taiber A, Hardisty L . A common haplotype in the complement regulatory gene factor H (HF1/CFH) predisposes individuals to age-related macular degeneration. Proc Natl Acad Sci U S A. 2005; 102(20):7227-32. PMC: 1088171. DOI: 10.1073/pnas.0501536102. View

14.

Lu Y, Brommer B, Tian X, Krishnan A, Meer M, Wang C . Reprogramming to recover youthful epigenetic information and restore vision. Nature. 2020; 588(7836):124-129. PMC: 7752134. DOI: 10.1038/s41586-020-2975-4. View

15.

Shibuya E, Meguro A, Ota M, Kashiwagi K, Mabuchi F, Iijima H . Association of Toll-like receptor 4 gene polymorphisms with normal tension glaucoma. Invest Ophthalmol Vis Sci. 2008; 49(10):4453-7. DOI: 10.1167/iovs.07-1575. View

16.

Mukai R, Okunuki Y, Husain D, Kim C, Lambris J, Connor K . The Complement System Is Critical in Maintaining Retinal Integrity during Aging. Front Aging Neurosci. 2018; 10:15. PMC: 5818470. DOI: 10.3389/fnagi.2018.00015. View

17.

Howell G, Soto I, Zhu X, Ryan M, Macalinao D, Sousa G . Radiation treatment inhibits monocyte entry into the optic nerve head and prevents neuronal damage in a mouse model of glaucoma. J Clin Invest. 2012; 122(4):1246-61. PMC: 3314470. DOI: 10.1172/JCI61135. View

18.

Sharma S, Bollinger K, Kodeboyina S, Zhi W, Patton J, Bai S . Proteomic Alterations in Aqueous Humor From Patients With Primary Open Angle Glaucoma. Invest Ophthalmol Vis Sci. 2018; 59(6):2635-2643. PMC: 6733532. DOI: 10.1167/iovs.17-23434. View

19.

Funke S, Perumal N, Bell K, Pfeiffer N, Grus F . The potential impact of recent insights into proteomic changes associated with glaucoma. Expert Rev Proteomics. 2017; 14(4):311-334. DOI: 10.1080/14789450.2017.1298448. View

20.

Luo C, Liu H, Wang H, Wang J . Toll-Like Receptor 4 Signaling in High Mobility Group Box-1 Protein 1 Mediated the Suppression of Regulatory T-Cells. Med Sci Monit. 2017; 23:300-308. PMC: 5267620. DOI: 10.12659/msm.902081. View